期刊文献+

替米沙坦对高血压患者左室与心肌指标的影响 被引量:1

Effects of telmisartan on left ventricular and myocardial parameters in patients with essential hypertension
原文传递
导出
摘要 目的探讨原发性高血压患者采用替米沙坦治疗后左室舒张功能与心肌肥厚的变化。方法选择2015年10月-2016年10月阳江市阳东区人民医院收治的原发性高血压伴左室舒张功能不全及左室肥厚的患者52例,对其采用替米沙坦治疗。观察本组治疗前与治疗1个疗程后患者血压、左室舒张功能与心肌肥厚指标的变化。结果本组治疗后收缩压(SBP)、舒张压(DBP)水平均低于治疗前,差异具有统计学意义(P<0.05)。本组治疗后IVST、LVPWT、LVMI、LVDd、A峰及A/E指标均低于治疗前,差异具有统计学意义(P<0.05);E峰指标高于治疗前,差异具有统计学意义(P<0.05)。结论原发性高血压患者采用替米沙坦治疗具有显著的降压效果,且能够改善患者左室舒张功能,调节心肌肥厚指标。 Objective To investigate the changes of left ventricular diastolic function and myocardial hypertrophy in patients with essential hypertension after the treatment with telmisartan. Methods 52 patients with essential hypertension, left ventricular diastolic dysfunction and left ventricular hypertrophy treated in Yangdong District People's Hospital of Yangjiang City from October 2015 to October 2016 were selected.All patients were treated with telmisartan. The changes of blood pressure, left ventricular diastolic function and myocardial hypertrophy were observed before and after 1 course of treatment. Results The levels of SBP and DBP in the group were lower than those before the treatment,the differences were statistically significant(P〈0.05). After treatment,the indexes of IVST,LVPWT,LVMI,LVDd,A peak and A/E were lower than those before treatment,the differences were statistically significant(P〈0.05). E peak index was higher than that before treatment,the difference was statistically significant(P〈0.05). Conclusion The treatment of telmisartan has significant antihypertensive effect on patients with essential hypertension, and this treatment can improve left ventricular diastolic function and regulate myocardial hypertrophy index.
出处 《中国城乡企业卫生》 2017年第5期103-105,共3页 Chinese Journal of Urban and Rural Enterprise Hygiene
关键词 原发性高血压 替米沙坦 左室舒张功能 心肌肥厚 Essential hypertension Telmisartan Left ventricular diastolic function Myocardial hypertrophy
  • 相关文献

参考文献5

二级参考文献40

  • 1陈凌,游晓华,潘静薇,秦永文,毕文杉,郑兴.替米沙坦治疗轻中度高血压患者降压效果及其安全性[J].药学服务与研究,2005,5(1):35-37. 被引量:8
  • 2崔英,方凤霄,李志红.替米沙坦治疗高血压病的临床研究[J].中国煤炭工业医学杂志,2005,8(10):1142-1143. 被引量:5
  • 3刘力生.中国高血压防治指南[M].北京:人民卫生出版社,2010:3.
  • 4国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:68.
  • 5Hohnes E,Loo R L,Stamler J,et al. Human metabolic phenotype diversity and its association with diet and blood pressure[J]. Nature, 2008,453 ( 7193 ) : 396.
  • 6Chobanian A V,Bakris G L,Black H R,et al.The seventh re-port of the joint national committee on prevention,detection,eval-uation and treatment of high blood pressure(the JNC report)[J].JAMA,2003,289(19):2560-73.
  • 7Mancia G,De Backer G,Dominiczak A,et al.The task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].J Hypertens,2007,25(6):1105-87.
  • 8Cushman W C,Ford C E,Cutler J A,et al.Success and predic-tors of blood pressure control in diverse North American settings:the antihypertensive and lipid-lowering treatment to prevent heart trial(ALLI-IAT)[J].J Clin Hypertens(Greenwich),2002,4(6):393-404.
  • 9Dahlof B,Sever P S,Poulter N R,et al.Prevention of cardiovas-cular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo Sacndinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomized controlled trial[J].Lancet,2005,366(9489):895-906.
  • 10Calhoun D A,Lacourciere Y,Chiang Y T,et al.Triple antihy-pertensive therapy with amlodipine,valsartan,and hydrochlorothi-azide:a randomized clinical trial [J].Hypertension,2009,54(1):32-9.

共引文献31

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部